Conciseness

The body is dense with operational specifics — tool names, parameter corrections, fallback chains, evidence thresholds — and mostly avoids explaining things Claude already knows. Minor trimmable redundancy exists: the 'LOOK UP, DON'T GUESS' section restates general agent behavior, OpenTargets endpoints are listed in PATH 0 and partially repeated in PATH 7, and the KEY PRINCIPLES list overlaps later sections. Efficient with minor over-explanation fits the 4 anchor; it is not the lean 'every token earns its place' of a 5.

Actionability

Guidance is executable, not abstract: a copy-paste `tu.tools.get_tool_info(...)` snippet, a ready-to-run GraphQL query example, six concrete retry chains (e.g., 'ChEMBL_get_target_activities fails → GtoPdb_search_ligands → OpenTargets drugs'), exact parameter corrections ('param is uniprot_id, not id'), and per-path tool lists with report-section mapping. Specific examples cover the common cases, matching the 5 anchor.

Workflow Clarity

The sequence is explicit and gated: identifier resolution always first, PATH 0 explicitly 'ALWAYS FIRST', then paths 1–8 with populates-mappings, a mandatory report-first scaffold, retry/fallback logic as feedback loops, and a REQUIRED 'Completeness Audit (REQUIRED before finalizing)' checklist including negative-results documentation. This matches the 5 anchor's explicit validation steps, feedback loops, and checklists.

Progressive Disclosure

The body is a genuine overview that pushes implementation detail to clearly signaled one-level-deep references (IMPLEMENTATION.md, EVIDENCE_GRADING.md, REPORT_FORMAT.md, REFERENCE.md, EXAMPLES.md) with a well-organized reference table at the end. However, none of the five referenced files exist in this bundle (no references/ directory or sibling files), so navigation breaks at read time — a real organization gap that keeps this at the 4 anchor rather than the 5 anchor's 'easy navigation'.

Specificity

The description enumerates multiple concrete capabilities with their source databases: "tissue expression (GTEx, HPA), pathways, protein interactions (STRING), variant landscape (ClinVar, gnomAD), druggability (DGIdb, ChEMBL approved drugs)" plus "9 parallel research paths with citations" — comprehensive, domain-specific coverage with no filler. This matches the anchor for multiple specific concrete actions with comprehensive coverage, not the score-4 anchor (which expects minor coverage gaps).

Completeness

Both questions are answered explicitly: the what is the enumerated capability list (expression, pathways, interactions, variants, druggability) and the when is a concrete "Use for full target profile reports, target characterization for drug discovery, and 'tell me about target X' queries" clause with concrete trigger phrases. This matches the 5 anchor exactly; the 4 anchor would require a weaker or less explicit 'when'.

Trigger Term Quality

Natural phrasing is present — "full target profile reports", "target characterization for drug discovery", and the directly user-quotable "'tell me about target X' queries" — but core nouns a user would naturally say, like "gene", "protein", or "drug target validation", are absent from the description. Good coverage with a few natural terms missing fits the 4 anchor; it does not reach the 5 anchor's comprehensive synonym coverage.

Distinctiveness Conflict Risk

The niche is clear — drug-target intelligence with named databases (GTEx, STRING, ClinVar, gnomAD, DGIdb, ChEMBL) — and unlikely to trigger for unrelated skills. However, the broad trigger phrase "tell me about target X" and the general 'target characterization' wording create minor overlap risk with simpler gene/protein-lookup or drug-lookup skills. Mostly distinct with minor overlap risk fits the 4 anchor; minimal conflict risk at 5 is not fully met.